louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02576925: A Predictive Score for the Ischemic Etiology of a Transient Diplopia (VASCO-DIP)
Official title: Development and Validation of a Predictive Score for the Ischemic Etiology of a Transient Diplopia
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Diplopia
Lead sponsor: Fondation Ophtalmologique Adolphe de Rothschild
Sponsor class: NETWORK
First posted: 2015-10-15
Enrollment: 220
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adults having had a transient diplopia during the last 8 days and seen at the fondation ophtalmologique Adolphe de Rothschild

Brief summary: The transient diplopias (TD) is defined by a short diplopia. Their etiology may be ophthalmological, neurological non-ischemic or of ischemic origin.

The difficulty is to recognize an ischemic mechanism which imposes emergency cares.

A clinical score could help the clinician to recognize the etiology of the TD .


Eligibility criteria: Inclusion Criteria:

* Transient diplopia (i.e. less than 24 hours) during the last 8 days

Exclusion Criteria:

-

Primary outcomes:
measure: Etiology, ischemic or not, of the initial transient diplopia
timeFrame: 3 months
Secondary outcomes:
measure: Incidence of new transient diplopia ischemic attacks during the 3 months of follow-up
timeFrame: 3 months
measure: Incidence of diplopia ischemic strokes during the 3 months of follow-up
timeFrame: 3 months
measure: Incidence of transient ischemic attacks, visual or not visual, during the 3 months of follow-up
timeFrame: 3 months
measure: Incidence of ischemic strokes, visual or not visual, during the 3 months of follow-up
timeFrame: 3 months
Other outcomes:
Locations:
city: Paris
country: France
facility: Fondation Ophtalmologique Adolphe de Rothschild
state: Ile De France
city: Paris
country: France
facility: Hôpital Bichat
Study officials:
References:
Clinical trial NCT01975025: Hemodialysis Frequency and the Calcification Propensity of Serum
Official title: Hemodialysis Frequency and the Calcification Propensity of Serum
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hemodialysis
Anuria
Keywords: Renal Dialysis
Lead sponsor: Insel Gruppe AG, University Hospital Bern
Sponsor class: OTHER
Collaborators: name: Baxter Healthcare Corporation
First posted: 2013-11-03
Enrollment: 17
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The aim of this clinical research project is to test the hypothesis that daily dialysis has favorable effects on the calcification propensity of human serum, when determined by the investigators' newly developed in vitro serum test. The investigators' hypothesis is that shorter interdialytic intervals will result in an improved calcification propensity of serum. The determination of serum calcification has the potential to become a novel measure of dialysis quality in the future.

Detailed description: Background

The serum calcification test has been established and validated by A. Pasch and coworkers, the expertise to perform the necessary statistical analyses is present in the investigator's department, all patient-related procedures necessary for this project are routinely performed in the investigator's department.

Objective

Does short daily hemodialysis strengthen the calcification-inhibitory forces inherent in hemodialysis patient sera, when compared to conventional three-times weekly hemodialysis?

Methods

Serum calcification test

Eligibility criteria: Inclusion Criteria:

* Chronic hemodialysis \>3 months
* Anuria (\<100ml urine per day)
* Written informed consent

Exclusion Criteria

* Citrate dialysis
* Significant fistula recirculation (\>15%)
* Infection

Primary outcomes:
measure: Change from baseline calcification propensity of serum
timeFrame: 6 weeks
Secondary outcomes:
measure: Change from baseline of sodium, potassium, calcium, phosphate, magnesium, albumin, protein, hematocrit and their correlation with calcification propensity of serum
timeFrame: 6 weeks
Other outcomes:
Locations:
city: Bern
country: Switzerland
facility: Dep. of Nephrology, Hypertension and Clinical Pharmacology, Bern University Hospital
Study officials:
affiliation: University Clinic Inselspital Bern
name: Andreas Pasch, PD. Dr. med.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02895425: Registry for End Stage Renal Failure
Official title: Réseau, Epidémiologie, Information, Néphrologie (Network Epidemiology Information Nephrology)
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: End Stage Renal Failure
Keywords: Renal Transplant
Lead sponsor: Centre Hospitalier de Cayenne
Sponsor class: OTHER
First posted: 2016-09-09
Enrollment: 1000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patient with End Stage Renal Failure followed in one of the dialisys sites in frnech Guiana

Brief summary: The rein registry collects case record data from patients with end stage renal disease followed in French Guiana. This allows to generate incidence and rates for terminal renal disease, mortality rates for each territory. The regional data are pooled in order to get national statistics for end stage renal disease and transplantation activity in order to adapt prevention to the main causes of renal failure and treatment and care infrastructure.


Eligibility criteria: Inclusion Criteria:

* End Stage Renal Failure

Exclusion Criteria:

* Refusal to participate

Primary outcomes:
measure: Death
timeFrame: 10 years
measure: Transplant
timeFrame: 10 years
Secondary outcomes:
Other outcomes:
Locations:
city: Cayenne
country: France
facility: General Hospital of Cayenne
state: French Guiana
Study officials:
References:
Clinical trial NCT01648725: Hypnosis and Closed-Loop Anesthesia System
Official title: Influence of Hypnosis on the Propofol Requirement to Induce General Anesthesia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Anesthesia
Keywords: Hypnosis
Anesthesia
Propofol
Closed-loop
Lead sponsor: Hopital Foch
Sponsor class: OTHER
First posted: 2012-07-24
Enrollment: 97
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Hypnosis may reduce patient anxiety. The main goal of this study is to determine in what extent, hypnosis decreases propofol requirement to induce induction of general anesthesia.

A particular aspect of this study is that induction is provided by a closed-loop system which delivers propofol according to bispectral index.


Eligibility criteria: Inclusion Criteria:

* adult patients scheduled for a surgical procedure under general anesthesia

Exclusion Criteria:

* pregnancy, breast feeding woman
* allergy to propofol, soy or peanuts
* history of central nervous system disease
* patient receiving a psychotropic treatment
* patient treated by a psychiatrist or a psychologist
* hypovolemia, high cardiovascular risk
* patients with a pace-maker

Primary outcomes:
measure: Administered dose of propofol required to obtain the induction of anesthesia (bispectral index <60 for at least 30 seconds)
timeFrame: one hour
Secondary outcomes:
measure: calculated target plasma concentration corresponding to induction of anesthesia (bispectral index <60 for at least 30 seconds)
timeFrame: one hour
measure: pain of injection
timeFrame: one hour
measure: Hemodynamic consequences of induction of anesthesia
timeFrame: one hour
measure: characteristics of the hypnotic procedure
timeFrame: one hour
measure: Patient assessment of the induction of anesthesia
timeFrame: one hour
measure: Time to loss of consciousness
timeFrame: one hour
Other outcomes:
Locations:
city: Suresnes
country: France
facility: Hopital Foch
Study officials:
affiliation: Hopital Foch
name: Barbara Szekely, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Liu N, Chazot T, Genty A, Landais A, Restoux A, McGee K, Laloe PA, Trillat B, Barvais L, Fischler M. Titration of propofol for anesthetic induction and maintenance guided by the bispectral index: closed-loop versus manual control: a prospective, randomized, multicenter study. Anesthesiology. 2006 Apr;104(4):686-95. doi: 10.1097/00000542-200604000-00012.
Clinical trial NCT03334825: Enhanced Housing Placement Assistance
Official title: An Enhanced Housing Placement Assistance (EHPA) Program for Homeless Persons Living With HIV/AIDS in New York City
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: HIV/AIDS
Housing Problems
Keywords: HIV
housing
homelessness
Lead sponsor: New York City Department of Health and Mental Hygiene
Sponsor class: OTHER_GOV
First posted: 2017-11-07
Enrollment: 236
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: randomized controlled trial
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Randomized controlled trial of housing placement assistance for homeless persons with HIV

Detailed description: Approximately 800 persons living with HIV/AIDS (PLWHA) reside in HIV emergency single-room-occupancy (SRO) hotels in New York City and do not have the ability to secure permanent housing on their own. The study evaluated a pilot program which fast-tracked PLWHA from HIV emergency SRO hotels into permanent housing. The Enhanced Housing Placement Assistance (EHPA) program had three components: 1) active recruitment of emergency SRO hotel residents with high need for housing; 2) assistance in the rapid (fast-track) acquisition of permanent housing; and 3) participation in a 12-month support services program designed to prevent PLWHA from relapsing into homelessness, with services focused on increasing clients' capacity to live independently and maintain housing stability. Participants were randomly assigned to either 1) EHPA or 2) usual care, which included standard connections to services and housing programs offered by the New York City HIV/AIDS Services Administration (HASA), Housing Opportunities for Persons With AIDS (HOPWA), or Ryan White services, and were followed over twelve months using a questionnaire developed with significant input from the target population of PLWHA residing in emergency SRO hotels.

Eligibility criteria: Inclusion Criteria:

* Person living with HIV in New York City
* Residing in an New York City HASA single-adult single-room-occupancy (SRO) hotel

Exclusion Criteria:

* Inability to provide informed consent
* Inability to complete survey in English or Spanish

Primary outcomes:
measure: Number of Participants With Placement in Permanent Housing
timeFrame: 12 months post-enrollment
Secondary outcomes:
measure: Number of Participants With Engagement in HIV Care
timeFrame: 12 months post-enrollment
measure: Number of Participants With HIV Viral Suppression
timeFrame: 12 months post-enrollment
Other outcomes:
Locations:
Study officials:
affiliation: New York City Department of Health and Mental Hygiene
name: Ellen W Wiewel, DrPH
role: PRINCIPAL_INVESTIGATOR
affiliation: RAND
name: Vivian L Towe, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00512525: Ghrelin Decreases Insulin Sensitivity
Official title: Intravenous Ghrelin Infusion Decreases Insulin Sensitivity in Healthy Young Men
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Subjects
Lead sponsor: University of Aarhus
Sponsor class: OTHER
First posted: 2007-08-07
Enrollment: 8
Sex: MALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Ghrelin administration increases appetite and, in rodents, induces weight gain. The aim of this study is to investigate the effect of short term ghrelin administration to humans on metabolism.

Detailed description: The current study is initiated in order to assess the impact of acute ghrelin administration on insulin resistance measured by a hyperinsulinemic euglycemic clamp. Second, as free fatty acid is the predominant substrate during fasting, we aim to asses the effects of ghrelin on local and systemic lipolysis.

Eligibility criteria: Inclusion Criteria:

* healthy men, age \>= 18 yr age \< 50 yr, body mass index \< 27.5 kg/m2above or equal to 18 yr

Exclusion Criteria:

* any disease, use of prescribed medication, age \< 18 yr or \>= 50 yr

Primary outcomes:
measure: Insulin sensitivity
timeFrame: End of clamp period
Secondary outcomes:
measure: Effects on lipolysis
timeFrame: End of basal and end og clamp period
Other outcomes:
Locations:
Study officials:
affiliation: Department of Pharmacology, University of Aarhus, Denmark
name: Ole Schmitz, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT04412525: Comparative Study 27G Vitrectomy vs Larger Gauge Surgery
Official title: Comparative Study 27G Vitrectomy vs Larger Gauge Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Vitreoretinal Surgery
Lead sponsor: Universitaire Ziekenhuizen KU Leuven
Sponsor class: OTHER
First posted: 2020-06-02
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Two-arm, mono-center, prospective, interventional comparative case study to compare postoperative recovery between the 27G and larger gauge surgical approach.

Detailed description: A prospective randomized comparison of postoperative recovery between 27-gauge and larger gauge surgical approaches to evaluate efficiencies and postoperative outcomes of the surgical gauges. Fifty patients who were scheduled to undergo pars plana vitrectomy (PPV) for floaters or macular surgery were treated with either 27-gauge or 23-gauge techniques and assessed for efficiency of the procedures as well as a variety of postop indicators of pain and inflammation.

Eligibility criteria: Inclusion Criteria:

* Patients aged over 18
* No prior vitrectomy surgery in the study eye (for the same eye)
* No prior inclusion in this trial
* Scheduled for vitrectomy for floater removal or macular surgery (including macular holes) without endotamponades such as PFCL, Gas, Silicone oil). (Air tamponade is allowed )

Exclusion Criteria:

* • Patients with serious heart, lung, liver, or kidney dysfunction

  * Patients with proliferative diabetic retinopathy, endophthalmitis, uveitis, eyes with refraction \>+5D or exceeding -8D , or other eye disease that impacts the outcome of vitrectomy surgery
  * Patients with HIV
  * Patients with history of drug abuse or alcoholism
  * Patients participating in other drug or medical device clinical trials before screening for this trial

Primary outcomes:
measure: changes in post-operative outcome of pain
timeFrame: day 1 postoperative
measure: changes in post-operative outcome of redness
timeFrame: day 1 postoperative
measure: changes in post-operative outcome in grading of anterior chamber cells
timeFrame: day 1 postoperative
Secondary outcomes:
measure: visual acuity
timeFrame: day 1 postoperative
measure: intra-ocular pressure
timeFrame: day 1 postoperative
measure: pain-assessment
timeFrame: 1 week postoperative
Other outcomes:
Locations:
city: Leuven
country: Belgium
facility: Universitaire Ziekenhuizen Leuven
Study officials:
affiliation: UZ Leuven
name: Peter Stalmans, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02727725: An Evaluation Of The Novel TRAMINER Sequence By Comparison To Late Gadolinium Enhancement Images
Official title: Establishing the Clinical Usefulness Of Dark Blood Late Gadolinium Enhancement Images For The Detection Of Small Subendocardial Left Ventricular Infarcts - An Evaluation Of The Novel TRAMINER Sequence By Comparison To Late Gadolinium Enhancement Images
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Myocardial Fibrosis
Cardiovascular Disease
Lead sponsor: Wake Forest University Health Sciences
Sponsor class: OTHER
Collaborators: name: Siemens Corporation, Corporate Technology
First posted: 2016-04-05
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: * The purpose of this study is to show that the novel TRAMINER (T(Rho) and Magnetization Transfer and Inversion Recovery) sequence provides at least as good visualization and detection of sub-endocardial scarring, fibrosis, and acute infarction as the current gold standard Inversion Recovery (IR) Turbo-Flash sequence.
* The hypothesis is that the TRAMINER sequence has the same or higher sensitivity in detecting small sub-endocardial scarring than the inversion recovery segmented gradient echo sequence known as IR-Turbo Fast low angle shot (IR Turbo-Flash), which is the accepted current gold standard for the detection of myocardial viability.


Eligibility criteria: Inclusion Criteria:

* Adults ≥18 years of age referred for a cardiac MRI with Gadolinium enhancement only at Advocate Lutheran General Hospital

Exclusion Criteria:

* \<18 years old,
* Adults unable to consent
* Adults for whom the MRI has not been previously scheduled
* Adults with an order for any MRI other than cardiac MRI with Gadolinium enhancement

Primary outcomes:
measure: Sensitivity of the TRAMINER sequence in detecting myocardial fibrosis or acute infarction compared to the gold standard sequence will be measured.
timeFrame: 6-12 months
Secondary outcomes:
measure: Reduction in clinical Magnetic Resonance (MRI) procedure time.
timeFrame: 6-12 months
Other outcomes:
Locations:
city: Park Ridge
country: United States
facility: Advocate Lutheran General Hospital
state: Illinois
Study officials:
affiliation: Advocate Lutheran General Hospital
name: Nayla Chaptini, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03062722: Efficacy of Keyhole Approach to Carpal Tunnel Syndrome Under Ambulatory Strategy
Official title: Efficacy of Keyhole Approach to Carpal Tunnel Syndrome Under Ambulatory
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Carpal Tunnel Syndrome
Entrapment Neuropathy
Keywords: microsurgical treatment
pain
dexterity
Phalen sign
functional status
Lead sponsor: University of Guadalajara
Sponsor class: OTHER
First posted: 2017-02-23
Enrollment: 55
Sex: ALL
Minimum age (years): 30
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Prospective controlled clinical trial in which a minimally invasive microsurgical approach was used following the keyhole principle in 55 patients and 65 hands under local anesthesia and ambulatory strategy. All patients included in the study had an average of 3 months disease course and were considered refractory to conservative treatment. Patients were evaluated with stringent inclusion criteria with the Levine severity and functional status scale with a 2 year follow-up. Descriptive outcomes on the efficiency of this procedure are reported.

Detailed description: Prospective clinical study to analyze 55 patients with carpal tunnel syndrome treated with open minimally invasive approach in 65 hands, using local anesthesia without tourniquet and in an ambulatory setting.

Eligibility criteria: Inclusion Criteria:

* Patients with confirmed diagnosis who had neurologic exam, electromyography, cervical spine X rays showing no structural disturbances and with at least 3 months of persistent pain refractory to medical management and physical therapy.

Exclusion Criteria:

* Patients with a history of direct trauma or orthopedic lesions in the carpal region, endocrine and/or metabolic disturbances (hypothyroidism, diabetes) and those that had previous local administration of steroids were excluded.

Primary outcomes:
measure: Levine Severity Scale
timeFrame: 2 years follow up
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Universidad se Guadalajara
name: Rodrigo Ramos Zuñiga, M.D. PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Ramos-Zuniga R, Garcia-Mercado CJ, Segura-Duran I, Zepeda-Gutierrez LA. Efficacy of Keyhole Approach to Carpal Tunnel Syndrome under Ambulatory Strategy. Neurol Res Int. 2017;2017:3549291. doi: 10.1155/2017/3549291. Epub 2017 Apr 6.
Clinical trial NCT02066922: A Comparative Study of Two Daily Disposable Contact Lenses in Higher Myopia Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Refractive Error
Myopia
Keywords: Contact lenses
Nearsightedness
Corneal curvature
K-reading
High minus
Spectacle refraction
Lead sponsor: Alcon Research
Sponsor class: INDUSTRY
First posted: 2014-02-20
Enrollment: 19
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare the change from baseline in central corneal curvature at one week, between 2 silicone hydrogel lenses, in higher myopic subjects.

Detailed description: Participants were expected to attend 4 office visits. Visit 1 was the Screening/Enrollment visit. At Visit 2 (Baseline Visit), participants were randomized and the study lenses were trial fit. At Visit 3 (Dispense Visit), participants received study lenses for approximately 1 week of wear. Visit 4 was the Exit visit. Expected duration of participation in the study was 3 weeks.

Eligibility criteria: Inclusion Criteria:

* Sign Informed Consent document;
* Higher degree of myopia in both eyes, i.e. habitual contact lens power between -10.00 diopters (D) and -17.00D;
* Best corrected distance visual acuity greater than or equal to 20/30 in each eye (measured with either spectacle refraction or habitual contact lenses plus over refraction);
* Manifest astigmatism less than or equal to -1.00D;
* Soft contact lens wear in both eyes at least 5 days per week and at least 8 hours per day;
* Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

* Pregnant or lactating;
* Eye injury or surgery within twelve weeks immediately prior to enrollment;
* Any ocular condition that contraindicates contact lens wear;
* History of herpetic keratitis;
* Any use of systemic or ocular medications for which contact lens wear could be contraindicated, including any use of topical ocular medications that would require instillation during contact lens wear, except for approved lubricating drops;
* Clinical significant dry eye not responding to treatment;
* Previous corneal or refractive surgery or irregular cornea;
* Requires reading glasses;
* Participation in a clinical trial (including contact lens or contact lens care product) within the previous 30 days;
* Wears habitual lenses in an extended wear modality (routinely sleeps in lenses overnight for 1 night per week or more) over the last 3 months prior to enrollment;
* Other protocol-defined exclusion criteria may apply.

Primary outcomes:
measure: Change in Average Central Corneal Curvature From Dispense at Week 1
timeFrame: Dispense (Day 1 of lens wear), Week 1 (Day 8 of lens wear)
Secondary outcomes:
measure: Number of Eyes With Change of >1.00 Diopter (D) in Spherical Equivalent of Subjective Refraction From Baseline at Week 1
timeFrame: Baseline, Week 1 (Day 8 of lens wear)
Other outcomes:
Locations:
Study officials:
affiliation: Alcon Research
name: Joachim Nick, Dipl. Ing.
role: STUDY_DIRECTOR
References: